A61K 47/6845
The antibody targeting a cytokine
Official title: {the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon}
A61K47/6845 (The antibody targeting a cytokine) appears on 304 US grants and 502 published applications in this corpus.
Search patents in A61K- Granted patents
- 304
- Published applications
- 502
- Assignees
- 231
- Inventors
- 1,060
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 2 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 3 | 0 |
| 1994 | 3 | 0 |
| 1995 | 3 | 0 |
| 1996 | 4 | 0 |
| 1997 | 11 | 0 |
| 1998 | 8 | 0 |
| 1999 | 2 | 0 |
| 2000 | 5 | 0 |
| 2001 | 3 | 0 |
| 2002 | 3 | 3 |
| 2003 | 2 | 5 |
| 2004 | 2 | 4 |
| 2005 | 2 | 3 |
| 2006 | 4 | 4 |
| 2007 | 4 | 5 |
| 2008 | 2 | 4 |
| 2009 | 3 | 10 |
| 2010 | 3 | 8 |
| 2011 | 5 | 7 |
| 2012 | 2 | 10 |
| 2013 | 5 | 17 |
| 2014 | 8 | 24 |
| 2015 | 9 | 22 |
| 2016 | 15 | 33 |
| 2017 | 15 | 46 |
| 2018 | 18 | 27 |
| 2019 | 26 | 34 |
| 2020 | 31 | 24 |
| 2021 | 15 | 38 |
| 2022 | 14 | 39 |
| 2023 | 16 | 31 |
| 2024 | 23 | 40 |
| 2025 | 20 | 39 |
| 2026 | 10 | 25 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Screening of fixed-point coupling sites of cysteine-modified antibody-toxin conjugate (TDC)14 Jul 2026US 12,678,474 B2
- Methods of treating an eye disorder2 Jun 2026US 12,643,958 B2Kodiak Sciences Inc.
- Antibody to insulin-like growth factor 1 receptor (IGF1R) and related compositions and uses12 May 2026US 12,624,110 B2Abl Bio Inc.
- Anti-human P40 protein domain antibody and use thereof7 Apr 2026US 12,595,300 B2Akeso Biopharma, Inc.
- Protease-cleavable substrates and methods of use thereof31 Mar 2026US 12,589,164 B1CytomX Therapeutics, Inc.
- Antibodies targeting s100 proteins and uses thereof1 Oct 2026US 2026/0297172 A1Albert Einstein College of Medicine
- Bispecific binding molecule binding to vegf and ang2 and use thereof17 Sep 2026US 2026/0274937 A1Innovent Biologics (Suzhou) Co., Ltd.
- Anti-tslp nanobodies and their applications17 Sep 2026US 2026/0274941 A1Shanghai Novamab Biopharmaceuticals Co., Ltd.
- Methods of treating an eye disorder17 Sep 2026US 2026/0274996 A1Kodiak Sciences Inc.
- Fc region-based heterodimer molecule and use thereof10 Sep 2026US 2026/0265361 A1
Most cited
By later US patents
- Diagnosis, removal, or mechanical damaging of tumor using plasmonic nanobubbles513US 10,471,159 B1Masimo Corporation · 2019
- Antibody compositions for selectively inhibiting VEGF356US 6,342,219 B12002
- Antibody conjugate compositions for selectively inhibiting VEGF181US 6,342,221 B12002
- Detection and treatment of infectious and inflammatory lesions159US 4,925,648 AImmunomedics, Inc. · 1990
- Methods and compositions for generating bioactive assemblies of increased complexity and uses128US 7,534,866 B2IBC Pharmaceuticals, Inc. · 2009